


Amendments to the Claims:


This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A process for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile of formula (I), a *N*-oxide, a pharmaceutically acceptable acid addition salt, a quaternary amine or a stereochemically isomeric form thereof,




(I)

which comprises reacting an intermediate of formula (II), an appropriate acid addition salt or a stereochemically isomeric form thereof



(II)

with an intermediate of formula (III), an appropriate acid addition salt or a *N*-oxide thereof




(III)

wherein W_1 represents a suitable leaving group, in the presence of a suitable solvent,

optionally followed, ~~if desired~~, by converting the free base into an acid addition salt by treatment with an acid, or alternatively, conversely, by converting the acid addition salt form into the free base by treatment with alkali; and optionally followed, ~~if desired~~, by preparing stereochemically isomeric forms, *N*-oxide forms or quaternary amines thereof.


2. (Original) A process according to claim 1 wherein the solvent is acetonitrile.

3. (Original) A process for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile of formula (I), a *N*-oxide, a pharmaceutically acceptable acid addition salt, a quaternary amine or a stereochemically isomeric form thereof



(I)


which comprises reacting an intermediate of formula (IV), an appropriate acid addition salt or a *N*-oxide thereof



(IV)


wherein W_2 represents a suitable leaving group, with acrylonitrile in the presence of a suitable palladium catalyst, a suitable base and a suitable solvent, optionally followed, ~~if desired~~, by converting the free base into an acid addition salt by treatment with an acid, or alternatively, conversely, by converting the acid addition salt form into the free base by treatment with alkali; and optionally followed, ~~if desired~~, by preparing stereochemically isomeric forms, *N*-oxide forms or quaternary amines thereof.

4. (Currently Amended) A process for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile of formula (I), a *N*-oxide, a pharmaceutically acceptable acid addition salt, a quaternary amine or a stereochemically isomeric form thereof




(I)

which comprises reacting an intermediate of formula (VI), an appropriate acid addition salt or a stereochemically isomeric form thereof




(VI)

with an intermediate of formula (III), an appropriate acid addition salt or a *N*-oxide thereof




(III)

wherein W_1 represents a suitable leaving group, in the presence of a suitable solvent, followed by dehydration of the thus obtained intermediate of formula (VII), a pharmaceutically acceptable acid addition salt, a stereochemically isomeric form or a *N*-oxide thereof,




optionally followed, ~~if desired~~, by converting the free base into an acid addition salt by treatment with an acid, or alternatively ~~conversely~~, by converting the acid addition salt form into the free base by treatment with alkali; and optionally followed, ~~if desired~~, by preparing stereochemically isomeric forms, *N*-oxide forms or quaternary amines thereof.

5. (Currently Amended) A process for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile of formula (I), a *N*-oxide, a pharmaceutically acceptable acid addition salt, a quaternary amine or a stereochemically isomeric form thereof




which comprises reacting an intermediate of formula (IV), an appropriate acid addition salt or *N*-oxide thereof




wherein W_2 represents a suitable leaving group, with acrylamide in the presence of a suitable palladium catalyst, a suitable base and a suitable solvent,

followed by dehydration of the thus obtained intermediate of formula (VII), a pharmaceutically acceptable acid addition salt, a stereochemically isomeric form or *N*-oxide thereof,




optionally followed, ~~if desired~~, by converting the free base into an acid addition salt by treatment with an acid, or alternatively, ~~conversely~~, by converting the acid addition salt form into the free base by treatment with alkali; and optionally followed, if desired, by preparing stereochemically isomeric forms, *N*-oxide forms or quaternary amines thereof.

6. (Currently Amended) A process for the preparation of an intermediate of formula (II), an appropriate acid addition salt, a quaternary amine or a stereochemically isomeric form thereof



which comprises reacting an intermediate of formula (V), an appropriate acid addition salt or a quaternary amine thereof




wherein W_3 represents a suitable leaving group, with acrylonitrile in the presence of a suitable palladium catalyst, a suitable base and a suitable solvent, optionally followed, ~~if desired,~~ by converting the free base into an acid addition salt by treatment with an acid, or alternatively, conversely, by converting the acid addition salt form into the free base by treatment with alkali; and optionally followed, ~~if desired,~~ by preparing stereochemically isomeric forms, *N*-oxide forms or quaternary amines thereof.

7. (Currently Amended) A process according to claim 3 ~~or claim 6~~ wherein the palladium catalyst is a heterogeneous palladium catalyst.


8. (Original) A process according to claim 7 wherein the heterogeneous palladium catalyst is palladium on charcoal.

9. (Currently Amended) A process for the preparation of an intermediate of formula (II), an appropriate acid addition salt, a quaternary amine or a stereochemically isomeric form thereof




(II)

which comprises reacting an intermediate of formula (V), an appropriate acid addition salt or a quaternary amine thereof



(V)

wherein W_3 represents a suitable leaving group, with acrylamide in the presence of a suitable palladium catalyst, a suitable base and a suitable solvent, followed by dehydration of the thus obtained intermediate of formula (VI), an appropriate acid addition salt, a quaternary amine or a stereochemically isomeric form thereof,




(VI)

optionally followed, ~~if desired~~, by converting the free base into an acid addition salt by treatment with an acid, or alternatively, conversely, by converting the acid addition salt form into the free base by treatment with alkali; and optionally followed, if desired, by preparing stereochemically isomeric forms, *N*-oxide forms or quaternary amines thereof.

10. (Currently Amended) A process according to claim 1 ~~any one of claims 1 to 5~~ wherein the 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile of formula (I), a *N*-oxide, a pharmaceutically acceptable acid addition salt, a quaternary amine or a stereochemically isomeric form thereof, is 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (E).

11. (Original) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]-amino]benzonitrile of formula (I), a *N*-oxide, a pharmaceutically acceptable acid addition salt, a quaternary amine or a stereochemically isomeric form thereof



(I)

12. (Original) A compound according to claim 11 wherein the compound is 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (E).